How to conduct effective market research in emerging markets
Pharmaceutical market research is still evolving in many emerging markets and so finding the insights you require can be a challenge.
In this webinar, using examples from a wide range of emerging markets, we will explain the important cultural, methodological and quality considerations and provide you with the core critical success factors to guaranteeing effective primary research in emerging markets.
The impact on patient outcomes in the treatment of non-radiographic axial spondyloarthritis
The Therapy Watch nr-axial SpA monthly study was launched in July 2014 among a panel of 200 EU5 rheumatologists to provide insight into the characteristics of nr-axSpA patients, existing treatment strategies and potential barriers to prescribing.
The Therapy Watch nr-axial SpA monthly study was launched in July 2014 among a panel of 200 EU5 rheumatologists to provide insight into the characteristics of nr-axSpA patients, existing treatment strategies and potential barriers to prescribing.Axial spondyloarthritis (axSpA) is still a relatively new term in rheumatology and the recent nomenclature separating axial vs. peripheral, and radiographic and non-radiographic spondyloarthritis has changed the perspective of ankylosing spondylitis (AS) by switching the focus towards earlier diagnosis and treatment of the disease.
Pricing wars heat up over hepatitis C drugs
The race for better hepatitis C treatments is in full swing with the approval of another all-oral drug regimen. The U.S. Food and Drug Administration (FDA) approved AbbVie’s new multi-drug combination, Viekira Pak, on December 19 last year, heightening the competition in the hepatitis C arena.
Sovaldi, Gilead’s oral treatment for hepatitis C costing $1,000 per pill, was cleared in the U.S. in December 2013, followed by the FDA approval of Harvoni at a cost of $1,125 per pill in October of last year. These two new Gilead drugs were launched at prices of $84,000 and $94,500 respectively for a 12-week regimen. In a battle to grab market share, AbbVie’s rival hepatitis C drug Viekira Pak costs $83,319 for a standard 12-week regimen.
EADV Congress 2015
Therapy Watch to present at the EADV Spring Symposium “real-world” patient data for PsO patients in disease remission
We are delighted to have been chosen to present a poster at this year’s EADV Spring Symposium in Valencia, Spain. The event will focus on topics such as skin cancer, inflammation and inflammatory skin diseases, psoriasis, infectious diseases, facial dermatosis, allergy and adnexal tumours.
Prostate Cancer Market Snapshot infographic
An overview of the prostate cancer patient
Download our Therapy Watch PCa market snapshot which provides you with an overview of the prostate cancer patient and the therapy regimens followed by the different patient segments.